IPHA
Innate Pharma S.A.
NASDAQ · Healthcare · Biotechnology · FR
$2.08
−1.42%Aug 14, 2026, 16:17 UTC
Innate Pharma S.A. announced an equity raise of EUR 30 million.
Aug 14, 2026, 16:17 UTC
Innate Pharma S.A. announced a strategic partnership.
Source:Aug 10, 2026, 06:00 UTC
Innate Pharma and Sobi announced a strategic partnership to license lacutamab for T-cell lymphoma, with Sobi receiving exclusive global commercialization rights and potential full development rights.
Jul 21, 2026, 06:00 UTC
Innate Pharma announced the completion of enrollment in the Phase 1 dose escalation study of IPH4502, a novel Nectin-4 exatecan antibody-drug conjugate.
Source: